C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

被引：10

作者：

Tada, Toshifumi ^{[1
]}

Kumada, Takashi ^{[2
]}

Hiraoka, Atsushi ^{[3
]}

Hirooka, Masashi ^{[4
]}

Kariyama, Kazuya ^{[5
]}

Tani, Joji ^{[6
]}

Atsukawa, Masanori ^{[7
]}

Takaguchi, Koichi ^{[8
]}

Itobayashi, Ei ^{[9
]}

Fukunishi, Shinya ^{[10
]}

Tsuji, Kunihiko ^{[11
]}

Ishikawa, Toru ^{[12
]}

Tajiri, Kazuto ^{[13
]}

Ochi, Hironori ^{[14
]}

Yasuda, Satoshi ^{[15
]}

Toyoda, Hidenori ^{[15
]}

Hatanaka, Takeshi ^{[16
]}

Kakizaki, Satoru ^{[17
]}

Shimada, Noritomo ^{[18
]}

Kawata, Kazuhito ^{[19
]}

Tanaka, Takaaki ^{[3
]}

Ohama, Hideko ^{[10
]}

Nouso, Kazuhiro ^{[5
]}

Morishita, Asahiro ^{[6
]}

Tsutsui, Akemi ^{[8
]}

Nagano, Takuya ^{[8
]}

Itokawa, Norio ^{[7
]}

Okubo, Tomomi ^{[7
]}

Arai, Taeang ^{[7
]}

Imai, Michitaka ^{[12
]}

Naganuma, Atsushi ^{[20
]}

Aoki, Tomoko ^{[21
]}

Koizumi, Yohei ^{[4
]}

Nakamura, Shinichiro ^{[1
]}

Joko, Kouji ^{[14
]}

Hiasa, Yoichi ^{[4
]}

Kudo, Masatoshi ^{[21
]}

机构：

[1] Japanese Red Cross Himeji Hosp, Dept Internal Med, 1-12-1 Shimoteno, Himeji, Hyogo 6708540, Japan

[2] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[3] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Ehime, Japan

[4] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Touon, Ehime, Japan

[5] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[6] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[7] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[8] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[9] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[10] Osaka Med Coll, Dept Gastroenterol, Osaka, Japan

[11] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan

[12] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[13] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[14] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Ehime, Japan

[15] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[16] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Gumma, Japan

[17] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Gumma, Japan

[18] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[19] Hamamatsu Univ Sch Med, Dept Hepatol, Hamamatsu, Shizuoka, Japan

[20] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Gumma, Japan

[21] Kindai Univ, Dept Gastroenterol & Hepatol, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2022年 / 12卷 / 01期

关键词：

LONG-TERM OUTCOMES; PROTEIN/ALBUMIN RATIO; CANCER; INFLAMMATION; SCORE; MANAGEMENT; SORAFENIB; SURGERY; IMPACT; INDEX;

D O I：

10.1038/s41598-022-12058-y

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib. We determined the optimal CAR cutoff value with time-dependent receiver operating characteristic curve analysis. Additionally, we clarified the relationship between CAR and liver function or HCC progression. Median overall survival was 20.0 (95% confidence interval (CI), 17.2-22.6) months. The optimal CAR cutoff value was determined to be 0.108. Multivariate analysis showed that high CAR (>= 0.108) (hazard ratio (HR), 1.915; 95% CI, 1.495-2.452), Eastern Cooperative Oncology Group performance status >= 1 (HR, 1.429), and alpha-fetoprotein >= 400 ng/mL (HR, 1.604) were independently associated with overall survival. Cumulative overall survival differed significantly between patients with low versus high CAR (p < 0.001). Median progression-free survival was 7.5 (95% CI, 6.7-8.1) months. Multivariate analysis showed that age, CAR >= 0.108 (HR, 1.644; 95% CI, 1.324-2.043), and non-hepatitis B, non-hepatitis C etiology (HR, 0.726) were independently associated with progression-free survival. Cumulative progression-free survival differed significantly between patients with low versus high CAR (p < 0.001). CAR values were significantly higher as Japan Integrated Staging score increased (p < 0.001). In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.

引用

页数：10

共 39 条

[31] Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib [J].

Tada, Toshifumi ;

Kumada, Takashi ;

Hiraoka, Atsushi ;

Michitaka, Kojiro ;

Atsukawa, Masanori ;

Hirooka, Masashi ;

Tsuji, Kunihiko ;

Ishikawa, Toru ;

Takaguchi, Koichi ;

Kariyama, Kazuya ;

Itobayashi, Ei ;

Tajiri, Kazuto ;

Shimada, Noritomo ;

Shibata, Hiroshi ;

Ochi, Hironori ;

Yasuda, Satoshi ;

Toyoda, Hidenori ;

Fukunishi, Shinya ;

Ohama, Hideko ;

Kawata, Kazuhito ;

Nakamura, Shinichiro ;

Nouso, Kazuhiro ;

Tsutsui, Akemi ;

Nagano, Takuya ;

Itokawa, Norio ;

Hayama, Korenobu ;

Arai, Taeang ;

Imai, Michitaka ;

Joko, Kouji ;

Koizumi, Yohei ;

Hiasa, Yoichi .

LIVER INTERNATIONAL, 2020, 40 (04) :968-976

[32] Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis [J].

Tada, Toshifumi ;

Kumada, Takashi ;

Toyoda, Hidenori ;

Kiriyama, Seiki ;

Tanikawa, Makoto ;

Hisanaga, Yasuhiro ;

Kanamori, Akira ;

Kitabatake, Shusuke ;

Yama, Tsuyoki .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (09) :1412-1419

[33] Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with Gastric Cancer [J].

Toiyama, Yuji ;

Shimura, Tadanobu ;

Yasuda, Hiromi ;

Fujikawa, Hiroyuki ;

Okita, Yoshiki ;

Kobayashi, Minako ;

Ohi, Masaki ;

Yoshiyama, Shigeyuki ;

Hiro, Jyunichiro ;

Araki, Toshimitsu ;

Inoue, Yasuhiro ;

Mohri, Yasuhiko ;

Kusunoki, Masato .

ANTICANCER RESEARCH, 2016, 36 (12) :6491-6498

[34] Differences in the impact of prognostic factors for hepatocellular carcinoma over time [J].

Toyoda, Hidenori ;

Kumada, Takashi ;

Tada, Toshifumi ;

Yama, Tsuyoki ;

Mizuno, Kazuyuki ;

Sone, Yasuhiro ;

Maeda, Atsuyuki ;

Kaneoka, Yuji ;

Akita, Tomoyuki ;

Tanaka, Junko .

CANCER SCIENCE, 2017, 108 (12) :2438-2444

[35] Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC [J].

Toyoda, Hidenori ;

Kumada, Takashi ;

Tada, Toshifumi ;

Sone, Yasuhiro ;

Kaneoka, Yuji ;

Maeda, Atsuyuki .

LIVER CANCER, 2015, 4 (02) :126-136

[36] A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection [J].

Toyoda, Hidenori ;

Kumada, Takashi ;

Tada, Toshifumi ;

Kaneoka, Yuji ;

Maeda, Atsuyuki .

SURGERY, 2015, 157 (04) :699-707

[37] A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma [J].

Xu, Xiao-Ling ;

Yu, Hui-Qin ;

Hu, Wei ;

Song, Qian ;

Mao, Wei-Min .

PLOS ONE, 2015, 10 (09)

[38]

YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO

[39]

2-3

← 1 2 3 4 →